What Is Rectal Cancer?
Rectal cancer is a type of cancer that originates in the cells lining the rectum — the final several inches of the large intestine just above the anus. In America, it represents one of the most discussed and studied cancer types, not just because of its prevalence, but because of a deeply troubling shift that public health authorities have been tracking closely. As of 2026, rectal cancer now accounts for 32% of all colorectal cancer (CRC) diagnoses in the United States, up from just 27% in the mid-2000s. That upward creep may seem small, but when you translate it into actual patient numbers, it tells a very different story — one of a disease quietly moving into younger age groups, getting diagnosed later, and in many cases becoming harder to treat.
What makes the 2026 rectal cancer landscape in America particularly significant is the generational divide being confirmed by federal and institutional data. While rectal cancer incidence has been declining among older adults aged 65 and above, rates are rising by 3% per year among adults aged 20 to 49, and 0.4% per year in those aged 50 to 64. The United States now faces a dual crisis — success in one demographic, and an alarming setback in another. This article brings together the most current verified statistics from the National Cancer Institute (NCI), the Centers for Disease Control and Prevention (CDC), the American Cancer Society (ACS), and the SEER (Surveillance, Epidemiology, and End Results) program to give you the clearest, most data-driven picture of rectal cancer in the US in 2026.
Interesting Rectal Cancer Facts in the US 2026
Before diving into the detailed statistics, here are the most critical and eye-opening facts about rectal cancer in America in 2026 — compiled from the latest federal and institutional data.
| Fact | Detail |
|---|---|
| Estimated new rectal cancer cases in 2026 | 49,990 |
| Rectal cancer share of all colorectal cancer cases | 32% (up from 27% in the mid-2000s) |
| Rectal cancer cases in men (2026) | 28,750 |
| Rectal cancer cases in women (2026) | 21,240 |
| Men are at higher risk for rectal cancer | 57% higher incidence rate compared to women |
| Rectal cancer incidence trend (all ages, 2018–2022) | +1% per year — reversing decades of decline |
| Incidence rise in adults aged 20–49 | +3% per year |
| Incidence rise in adults aged 50–64 | +0.4% per year |
| Adults under 65 now share of new CRC diagnoses | 45% (up from 27% in 1995) |
| CRC diagnoses in people under 65 per day | ~200 per day |
| #1 cancer killer in adults under 50 | Colorectal cancer (incl. rectal) |
| Rectal cancer share among under-50 diagnoses with advanced stage | 3 in 4 (75%) are advanced-stage at diagnosis |
| Distant-stage (metastatic) rectal cancer survival improvement | From 8% (mid-1990s) to 18% (current) |
| 5-year relative survival for localized rectal cancer | ~91% |
| 5-year relative survival for distant (metastatic) rectal cancer | ~15% |
| Alaska Native people CRC incidence rate | 80.9 per 100,000 — highest globally |
| Colonoscopy effectiveness on CRC incidence | Reduces incidence by ~40% |
| Colonoscopy effectiveness on CRC mortality | Reduces mortality by ~60% |
| US CRC screening rate in adults 45+ | 65% (up from 59% in 2021) |
| CRC survivors in the US as of 2025 | More than 1.4 million |
| CRC mortality decline since 1970 | 56% overall drop |
Source: American Cancer Society Colorectal Cancer Statistics 2026; NCI SEER Program; CDC National Center for Health Statistics; CA: A Cancer Journal for Clinicians, March 2026
The facts table above paints a picture that is both hopeful and deeply concerning. The dramatic reduction in CRC mortality since 1970 — down 56% — shows just how far screening and treatment have come. And yet the reversal of a decades-long decline in rectal cancer incidence, the growing share of younger Americans being diagnosed, and the persistent racial disparities remind us that the fight is far from won.
What stands out most is the speed of change. In just two decades, rectal cancer’s share of all CRC diagnoses has grown from 27% to 32%. The fact that 75% of rectal cancer cases in adults under 50 are diagnosed at an advanced stage is particularly alarming — not just from a survival standpoint, but because it highlights a systemic failure in early detection among younger populations. These aren’t small numbers or marginal trends. They represent thousands of Americans each year being diagnosed too late, and a healthcare system that was not designed to anticipate cancer in people in their 30s and 40s. The improvement in distant-stage rectal cancer survival from 8% to 18% is a genuine breakthrough, but a survival rate of 15% for metastatic disease still means that most patients diagnosed at that stage will not survive beyond five years.
Rectal Cancer New Cases and Incidence in the US 2026
Estimated New Rectal Cancer Diagnoses in the US 2026
| Category | Estimated Cases (2026) |
|---|---|
| Total new rectal cancer cases | 49,990 |
| Rectal cancer in men | 28,750 |
| Rectal cancer in women | 21,240 |
| Total new colorectal cancer (CRC) cases | 158,850 |
| Colon cancer (for reference) | 108,860 |
| Rectal cancer as % of total CRC | 31.5% |
| Rate of new CRC cases per 100,000 | 37.1 (age-adjusted, 2018–2022) |
| Annual CRC incidence trend (2013–2022, all ages) | -0.9% per year overall |
| Annual incidence trend — adults 65+ | -2.5% per year |
| Annual incidence trend — adults 20–49 | +3% per year |
| Annual incidence trend — adults 50–64 | +0.4% per year |
| Rectal cancer incidence trend (all ages, 2018–2022) | +1% per year |
Source: American Cancer Society Colorectal Cancer Statistics 2026; NCI SEER Program; CDC National Program of Cancer Registries; CA: A Cancer Journal for Clinicians (Siegel et al., March 2026)
The 2026 rectal cancer incidence data from the American Cancer Society tells a story of a disease diverging sharply across age groups. The estimated 49,990 new rectal cancer cases for this year confirm that rectal cancer is not declining — it is trending upward in overall terms after years of decline, driven almost entirely by younger cohorts. The annual rate among adults 20 to 49 growing at +3% per year is extraordinarily fast for a cancer that was once considered almost exclusively a disease of older adults.
What makes this shift particularly relevant for rectal cancer in the US in 2026 is that it is being led by tumors in the distal colon and rectum specifically — the anatomic sites most associated with environmental and dietary exposures. The trend in adults aged 50 to 64 — growing at +0.4% per year while the 65+ group continues to improve — suggests that whatever is driving early-onset disease has been affecting a wider age range for longer than previously appreciated. The reversal of the rectal cancer incidence trend from declining to +1% per year between 2018 and 2022 represents one of the most closely watched developments in American oncology right now.
Rectal Cancer Deaths and Mortality in the US 2026
Estimated Rectal Cancer and CRC Mortality in the US 2026
| Mortality Metric | Data (2026) |
|---|---|
| Total estimated CRC deaths in 2026 | 55,230 |
| CRC deaths in adults under 65 | ~18,410 (nearly one-third) |
| CRC death rate per 100,000 (2019–2023) | 12.9 (age-adjusted) |
| CRC mortality trend — adults under 50 | +1% per year since 2004 |
| CRC mortality trend — adults 50–64 | +1% per year since 2019 |
| CRC mortality trend — adults 65+ | -2% to -3% per year since 1990s |
| Overall CRC mortality decline since 1970 | 56% (from 29.1 to 12.7 per 100,000) |
| Mortality trend (2020–2023) | Stable (no decline) |
| CRC rank as cause of cancer death — men | 3rd leading |
| CRC rank as cause of cancer death — women | 4th leading |
| CRC rank combined men + women | 2nd most common cancer death |
| CRC rank as cancer death cause — adults under 50 | #1 (top cause) |
Source: National Center for Health Statistics (NCHS/CDC); American Cancer Society Cancer Facts & Figures 2026; NCI SEER Program; CA: A Cancer Journal for Clinicians (January 2026)
The rectal and colorectal cancer mortality data for 2026 highlights a paradox that public health officials have been grappling with for years. The overall 56% drop in CRC mortality since 1970 is one of the great success stories of American cancer prevention — driven by the widespread adoption of colonoscopy screening and lifestyle awareness. Yet when you break down the mortality trends by age, the picture becomes far more troubling. CRC death rates in adults under 50 have been climbing at +1% per year since 2004 — two full decades of worsening outcomes in what should be the prime of life.
The fact that mortality trends among adults 65 and older continue to improve at 2% to 3% per year while the under-50 and 50-to-64 age groups are seeing rising death rates suggests that screening — which has historically been targeted at adults 50 and older — has played a major role in the older age group’s improvement. The 2021 update to screening guidelines lowering the recommended start age to 45 may gradually shift these trends, but the data from 2026 has not yet reflected that benefit. The stabilization of overall CRC mortality from 2020 to 2023 — after decades of consistent decline — is a warning signal that the gains among older adults may no longer be enough to offset the losses in younger populations.
Rectal Cancer Survival Rates in the US 2026
5-Year Rectal Cancer Relative Survival Rates by Stage in the US 2026
| Stage at Diagnosis | 5-Year Relative Survival Rate |
|---|---|
| Localized (cancer confined to rectum) | ~91% |
| Regional (spread to nearby lymph nodes/tissue) | ~69% |
| Distant (metastatic — spread to other organs) | ~15% |
| All stages combined (CRC overall) | ~65% (2015–2021) |
| Distant-stage rectal cancer survival (mid-1990s) | 8% |
| Distant-stage rectal cancer survival (current) | 18% |
| Overall 5-year CRC survival (mid-1970s baseline) | 50% |
| 5-year CRC survival (2015–2021) | 65% |
| 5-year survival — regional-stage disease | 69% |
| 5-year survival — distant-stage disease (all CRC) | 35% |
| Localized stage share — adults 65+ at diagnosis | ~35% |
| Localized stage share — adults under 50 at diagnosis | ~26% |
| Advanced stage (regional or distant) — adults under 50 | ~75% |
Source: NCI SEER Database (SEER 21, 2015–2021); American Cancer Society Cancer Facts & Figures 2026; CA: A Cancer Journal for Clinicians (January 2026); PMC Cancer Statistics 2026
Survival rates for rectal cancer in the US have improved meaningfully over the past three decades, and the data for 2026 reflects some genuinely encouraging progress. The increase in distant-stage rectal cancer survival from 8% to 18% since the mid-1990s is one of the most notable gains in the entire cancer landscape — a more than doubling of the survival probability for patients diagnosed with metastatic disease. This improvement is credited to more precise surgical techniques, better chemotherapy regimens, and the introduction of targeted biological therapies.
Still, the survival numbers expose a fundamental truth about rectal cancer outcomes in 2026: stage at diagnosis is overwhelmingly determinative of survival. The gap between 91% localized survival and 15% distant-stage survival is one of the starkest in oncology. This is why the statistic that 75% of rectal cancers in adults under 50 are diagnosed at an advanced stage is so devastating — those patients are starting their treatment journey at the worst possible point on the survival curve. The rise in overall CRC survival from 50% in the mid-1970s to 65% today is a direct result of earlier detection through screening, reinforcing why expanding access to colonoscopy and stool-based testing in younger populations is not just a policy option but a medical imperative.
Rectal Cancer by Age Group in the US 2026
Rectal Cancer Age-Specific Trends in the US 2026
| Age Group | Incidence Trend | Key Stat |
|---|---|---|
| Adults under 50 (early-onset) | +3% per year (2013–2022) | #1 cancer cause of death in this group |
| Adults aged 45–49 | Rising | 50% of under-50 CRC diagnoses are in this group |
| Adults aged 50–64 | +0.4% per year | Increasing in regional & distant stage (+1.1%–1.3%/yr) |
| Adults aged 65+ | -2.5% per year | Continuing decade-long decline |
| Adults under 65 share of new CRC diagnoses (2026) | — | 45% (up from 27% in 1995) |
| Adults under 65 share of CRC deaths (2026) | — | Nearly one-third |
| Advanced-stage diagnosis — adults under 50 | — | 75% (3 in 4) |
| Distant-stage — adults under 50 | — | 27% |
| Early-onset CRC incidence rise — all racial groups | — | +3% per year in AIAN, AANHPI, White populations |
| CRC mortality trend — adults 50–64 | +1% per year since 2019 | Rising |
| CRC mortality trend — adults under 50 | +1% per year since 2004 | Rising for 20+ years |
Source: American Cancer Society Colorectal Cancer Statistics 2026; NCI SEER Program; CDC National Program of Cancer Registries; CA: A Cancer Journal for Clinicians (Siegel et al., March 2026)
The age-based rectal cancer data for 2026 confirms what researchers have been warning about for years — this is no longer primarily a disease of older adults. The shift is stark: 45% of all new CRC diagnoses in 2026 are in people under 65, compared to just 27% in 1995. That is not a gradual drift — it is a fundamental restructuring of who gets this disease in America. The fact that 50% of all under-50 colorectal cancer diagnoses are in adults aged 45 to 49 is especially telling, since this is the precise age group now covered by the lowered screening guidelines from 2021. It means that catching these patients at 45 — before symptoms appear — is both scientifically justified and potentially life-saving.
The reason the under-50 group faces such a disproportionate burden of advanced-stage disease at diagnosis comes down to a combination of factors: a historical lack of screening in this age group, a cultural assumption that younger people are not at risk for colorectal cancer, and the tendency for symptoms like rectal bleeding or change in bowel habits to be dismissed as hemorrhoids or IBS in younger patients. The rising mortality in the 50-to-64 age group since 2019 — despite decades of decline — suggests that the cohort of younger adults with elevated risk is now aging into that bracket, and bringing their elevated disease burden with them. These are generational trends, and addressing them will require generational interventions.
Rectal Cancer by Race and Ethnicity in the US 2026
Racial and Ethnic Disparities in Rectal Cancer — US 2026
| Racial / Ethnic Group | Key Statistic |
|---|---|
| Alaska Native | 80.9 per 100,000 CRC incidence — highest globally |
| Alaska Native — mortality rate | 31.5 per 100,000 — more than 2x White rate |
| American Indian | 2nd highest CRC burden in the US |
| Black-White CRC incidence disparity (2022) | 11% higher in Black Americans vs. White (narrowed from 22% in 2013) |
| AIAN-White CRC incidence disparity (2022) | 48% higher in AIAN vs. White (widened from 39% in 2013) |
| Non-Hispanic Black screening rate (2023) | 62% among eligible adults 50+ |
| Non-Hispanic White screening rate (2023) | 80.1% among eligible adults |
| American Indian / Alaska Native screening rate (2023) | 48.65% — lowest of all groups |
| Uninsured adults CRC screening rate (2023) | 33.02% |
| Insured adults CRC screening rate (2023) | 78.13% |
| Black Americans distant-stage CRC diagnosis share | 25% vs. 21% in White Americans |
| 5-year CRC survival — Black individuals | ~60% |
| 5-year CRC survival — Asian American/Pacific Islander | ~67% |
| Screening disparities accounting for Black-White CRC incidence gap | ~42% of the disparity |
Source: American Cancer Society Colorectal Cancer Statistics 2026; ACS Cancer Disparities Report 2025; NCI SEER Program; CDC BRFSS; Digestive Diseases and Sciences (Eldesouki et al., November 2025)
The racial and ethnic disparities in rectal cancer and CRC in the US represent one of the most persistent and morally urgent problems in American health care. The Alaska Native population carries the heaviest burden of any group in the world — an incidence rate of 80.9 per 100,000, more than double that of White Americans, with a mortality rate that is similarly extreme. Researchers have noted that the causes remain poorly understood, partly due to a lack of dedicated research funding for this relatively small but profoundly affected population. The American Indian population faces the second-highest CRC burden in the country, and unlike the Black-White disparity — which has narrowed slightly — the AIAN-White gap has actually widened from 39% to 48% between 2013 and 2022, suggesting that the interventions that have worked for other groups are not reaching these communities.
The screening data by race and insurance status is where the policy implications become most direct. A screening rate of just 33.02% among uninsured adults compared to 78.13% among insured adults is a difference that translates directly into lives lost. For the Alaska Native and American Indian populations, a screening rate of 48.65% in 2023 means that most at-risk individuals are not being reached. The fact that 42% of the Black-White CRC incidence gap can be attributed to screening differences alone tells us that this is not primarily a biological story — it is a story about access, insurance, geography, and structural inequity. Closing these gaps is not just an ethical imperative. The data shows clearly that it would prevent a substantial and quantifiable number of cancer deaths each year.
Rectal Cancer Screening Rates in the US 2026
CRC Screening Rates and Trends in the US 2026
| Screening Metric | Data |
|---|---|
| Adults 45+ up-to-date with CRC screening (2023) | 65% |
| Adults 45+ up-to-date with CRC screening (2021) | 59% |
| Screening rate increase (2021–2023) | +6 percentage points |
| NCCRT goal — adults 45+ screened | 80% |
| CRC screening rate increase (2012–2018) | Added 9.3 million more adults screened |
| Federally Qualified Health Center patients screened (2024) | 3,617,246 (up 9.4% from 2023) |
| CRCCP — people screened (July 2021 – June 2022) | ~198,000 (35% increase) |
| Colonoscopy — reduction in CRC incidence | ~40% |
| Colonoscopy — reduction in CRC mortality | ~60% |
| Screening start age (current guideline, average-risk adults) | Age 45 |
| Screening prevalence — ages 45–49 (lowest eligible group) | Below national average |
| Overall CRC screening rate trend (1999–2023) | From 41.5% to 76.3% |
| National CRC screening rate among adults 50–75 (BRFSS 2023) | 76.3% |
Source: National Colorectal Cancer Roundtable (NCCRT); CDC Behavioral Risk Factor Surveillance System (BRFSS) 2023; HRSA Health Center Data 2024; CDC Colorectal Cancer Control Program (CRCCP); National Health Interview Survey 2019–2023
Colorectal cancer screening rates in the US have come a long way since 1999, when just 41.5% of eligible adults were being screened. The rise to 76.3% overall by 2023 represents decades of public health campaigns, clinical guideline changes, and program investments. The +6 percentage point jump from 59% to 65% among adults aged 45 and older between 2021 and 2023 is promising — particularly because it follows the 2021 guideline change that expanded screening eligibility to include age 45 for average-risk adults. The fact that Federally Qualified Health Centers screened 3.6 million patients in 2024 — nearly 10% more than in 2023 — shows that community health infrastructure is actively responding.
But the gap between the current 65% screening rate and the 80% national goal set by the NCCRT still represents millions of Americans who are not being tested. The group with the lowest screening uptake remains adults aged 45 to 49 — the very same group that now accounts for 50% of all under-50 CRC diagnoses. The screening system caught up to this group in guideline terms in 2021, but behavioral adoption lags. A major obstacle documented in recent research is that even among patients who receive a positive stool-based test, follow-up colonoscopy is frequently delayed — undermining the entire point of the screening chain. This combination of under-screening and inadequate follow-up is a critical bottleneck in the US’s ability to reduce rectal cancer incidence and mortality in 2026 and beyond.
Rectal Cancer and Gender Differences in the US 2026
Sex-Based Rectal Cancer Differences in the US 2026
| Gender Metric | Data |
|---|---|
| New rectal cancer cases — men (2026) | 28,750 |
| New rectal cancer cases — women (2026) | 21,240 |
| Overall CRC incidence — men vs. women | Men are 32% higher (40.5 vs. 30.7 per 100,000) |
| Rectal cancer specifically — men vs. women incidence | Men are 57% higher |
| Distal colon cancer — men vs. women incidence | Men are 41% higher |
| Proximal colon — men vs. women incidence | Men are only 9% higher |
| CRC incidence difference — men vs. women under 50 | Men are only 19% higher (narrower gap) |
| CRC incidence difference — men vs. women aged 50–64 | Men are 44% higher |
| Distal colon cancer under 50 — men vs. women | Equivalent rates |
| Total new CRC cases — men (2026) | 84,160 |
| Total new CRC cases — women (2026) | 74,690 |
| Lifetime risk of CRC — men | ~1 in 24 |
| Lifetime risk of CRC — women | ~1 in 26 |
Source: American Cancer Society Colorectal Cancer Statistics 2026; NCI SEER Program; CA: A Cancer Journal for Clinicians (Siegel et al., March 2026)
The gender gap in rectal cancer is one of the most pronounced of any cancer subtype within the colorectal category. While men have a 32% higher overall CRC incidence compared to women, the disparity is especially sharp for rectal cancer specifically, where men’s incidence rate is 57% higher than women’s. This anatomical specificity — where the sex gap narrows toward the proximal colon and widens toward the rectum — suggests that hormonal factors, particularly estrogen’s potential protective role in the distal bowel, may be at play. It also points toward distinct carcinogenic exposures that vary by anatomic location and biological sex.
The finding that the sex gap narrows significantly among adults under 50 — with men only 19% higher than women, compared to 44% higher in the 50-to-64 age group — is scientifically important for understanding early-onset disease. For the distal colon specifically, rates among men and women under 50 are actually equivalent, which is unusual across the colorectal spectrum. This convergence in younger age groups has been attributed to shared environmental exposures and lifestyle risk factors — including diet, obesity, sedentary behavior, and alcohol use — that are increasingly common across both sexes in younger American generations. As these younger cohorts age, tracking how the gender gap evolves will be an important data point for understanding what is driving the early-onset trend.
Rectal Cancer Survivors and Prevalence in the US 2026
CRC Survivors and Prevalence Data in the US 2026
| Prevalence / Survivor Metric | Data |
|---|---|
| Total CRC survivors in the US (as of 2025) | More than 1.4 million |
| Lifetime risk of developing CRC — all Americans | ~3.9% (approx. 1 in 26) |
| Overall cancer deaths averted since 1991 (all types) | 4.8 million |
| 5-year overall cancer survival rate (2015–2021) | 70% (milestone) |
| 5-year CRC survival (all stages) | ~65% |
| 5-year CRC survival improvement since mid-1970s | From 50% to 65% |
| 5-year CRC survival — adults aged 50–64 | ~70% |
| 5-year CRC survival — adults aged 65+ | ~60% |
| 5-year CRC survival — Black individuals | ~60% |
| 5-year CRC survival — Asian American/Pacific Islander | ~67% |
| Improvements in myeloma survival (for comparison) | 32% → 62% (biggest gain) |
| Improvements in metastatic rectal cancer survival | 8% → 18% (more than doubled) |
| CRC incidence and mortality drop — adults 50+ over 15 years | Over 30% |
Source: NCI SEER Database; American Cancer Society Cancer Facts & Figures 2026; CA: A Cancer Journal for Clinicians (January 2026); CDC National Center for Health Statistics
The more than 1.4 million CRC survivors in the United States as of 2025 represent one of the most tangible proofs of progress in cancer medicine. This is a population that has benefited from decades of improved screening, more sophisticated imaging and staging tools, and treatment advances that have made even metastatic disease survivable for longer than ever before. The 5-year overall cancer survival rate reaching a milestone 70% for diagnoses between 2015 and 2021 reflects these compounding gains — and for rectal cancer specifically, the more than doubling of distant-stage survival from 8% to 18% is one of the standout achievements of modern oncology.
That said, the survival data also exposes where the system still falls short. The 10-percentage-point gap in 5-year survival between Black Americans (60%) and Asian American/Pacific Islander individuals (67%) reflects structural inequities in access to early-stage diagnosis and quality treatment. Similarly, the lower survival rates among adults 65 and older compared to those aged 50 to 64 partly reflect comorbidities that limit treatment options, but also highlight age-related gaps in care intensity. For rectal cancer in the US in 2026, the survivor community is growing — but growing equitably is the next frontier. The patients most likely to become survivors are those diagnosed early, insured, and living in areas with access to specialized colorectal cancer care. Changing those eligibility conditions is where the next decade of public health progress needs to focus.
Disclaimer: The data reports published on The Global Files are sourced from publicly available materials considered reliable. While efforts are made to ensure accuracy, no guarantees are provided regarding completeness or reliability. The Global Files is not liable for any errors, omissions, or damages resulting from the use of these reports.